Samaritan Partners 'Forgetful' Rat Model to Taconic to Commercialize
01 October 2008 - 11:59PM
PR Newswire (US)
The Samaritan Alzheimer's Rat Model LAS VEGAS, Oct. 1
/PRNewswire-FirstCall/ -- Samaritan Pharmaceuticals (OTC:SPHC)
(BULLETIN BOARD: SPHC) (http://www.samaritanpharma.com/) and
Taconic Farms, Hudson, New York, are pleased to announce they have
inked a worldwide partnering agreement to commercialize "The
Samaritan Alzheimer's Rat Model." The "forgetful" rat model is a
research tool used by scientists to study the effectiveness of
their new drugs to treat Alzheimer's disease. The unique benefits
of the rat model lie in its ability, -- To mimic many features of
human Alzheimer's including memory loss, -- Speed a scientist's
"race for time" in finding a cure for the mind-robbing disease --
Save scientists valuable research money. (Photo:
http://www.newscom.com/cgi-bin/prnh/20081001/LAW054) The rat model
is now available exclusively through Taconic. Samaritan will
receive royalties on net sales. Financial terms were not disclosed.
"Taconic is extremely pleased to offer researchers a new and
potentially invaluable weapon in the war on neurodegenerative
disease," said Todd Little, President of Taconic. "The rapid time
to disease state of the Samaritan Alzheimer's Rat Model will enable
investigators to conduct Alzheimer's drug target screening on a
much faster timeline than ever before." The rat model is published
in Pharmacology, 2006;76:19-33 "Taconic provides us with an
experienced partner to monetize this unique animal model to 'rat
out' Alzheimer's. The rat model is groundbreaking, in that it
offers significant advantages over other options previously
available for the study of Alzheimer's. We anticipate Taconic
achieving and surpassing projected market penetrations in
international markets," said Dr. Greeson, CEO, Samaritan
Pharmaceuticals. Samaritan's Phase I, Alzheimer's drug Caprospinol
(SP-233), utilized "The Samaritan Alzheimer's Rat Model." and the
Morris Water Maze, in an IND enabling, proof of concept study.
Treated rats demonstrated Caprospinol's efficacy by, -- clearing
beta-amyloid plaque formation -- restoring the memory of tested
rats -- protecting mitochondria function -- protecting cell
viability -- decreasing cell death Samaritan Pharmaceuticals:
"Transforming Today's Science Into Tomorrow's Cures." Samaritan
Pharmaceuticals is a biopharmaceutical company committed to
bringing innovative life-saving drugs to suffering patients.
Samaritan website: http://www.samaritanpharma.com/. Please register
for upcoming conference calls, news, and events. Taconic Farms,
Inc. Taconic was founded in 1952 as a family-owned business in New
York's Hudson River Valley. Since then, the company has become one
of the largest laboratory rodent providers in the world with a
reputation for consistently producing high quality, well-defined
rats and mice. Taconic has six breeding facilities and three
service laboratories in the USA and Europe, a staff of over 900,
and a commitment to technological innovation. Taconic website,
http://www.taconic.com/ Disclaimer The company disclaims any
information created by an outside party and endorses only
information communicated by its press releases, filings, and
website. This news release contains forward-looking statements that
reflect management's current beliefs about the potential for its
drug candidates, science, and technology. For additional
information about the factors that affect the company's business,
please read the company's latest Form 10-K filed April 14, 2008.
The company undertakes no duty to update forward-looking
statements. Samaritan Pharma Contact: Barrie Fuller 702-735-7001
http://www.newscom.com/cgi-bin/prnh/20081001/LAW054 DATASOURCE:
Samaritan Pharmaceuticals CONTACT: Barrie Fuller of Samaritan
Pharmaceuticals, +1-702-735-7001, Web site:
http://www.samaritanpharma.com/ http://www.taconic.com/ Company
News On-Call: http://www.prnewswire.com/comp/158311.html
Copyright